iCirculation/
Articles/
2603003201
  • Open Access
  • Review

The Latest Progress of Targeting Fibroblast Activating Protein PET/CT Molecular Imaging in Heart Failure

  • Haoran Guo 1,2,   
  • Jianming Li 1,2,*

Received: 16 Dec 2025 | Revised: 15 Feb 2026 | Accepted: 04 Mar 2026 | Published: 18 Mar 2026

Abstract

Heart failure (HF), the devastating end-stage manifestation of numerous cardiovascular diseases, exhibits alarmingly high morbidity, recurrent hospitalization rates, and mortality. At the core of this pathology lies myocardial fibrosis. Early detection, precise classification, dynamic monitoring, and rigorous assessment of treatment response for myocardial fibrosis are crucial for advancing precision management of HF. In recent years, fibroblast activation protein (FAP)-targeted molecular imaging—specifically fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT)—has garnered considerable attention. This innovative technology uniquely enables the visualization and quantitative assessment of myocardial fibrosis at the molecular level. This review synthesizes the latest research progress on FAPI PET/CT in HF, emphasizing its promising potential for application in the early diagnosis, risk stratification, and prediction of outcomes related to myocardial fibrosis. It also critically examines existing technical limitations and explores prospects for future research.

Graphical Abstract

Image Viewer
Open in new tab
Download Image

References 

  • 1.

    Bozkurt, B.; Ahmad, T.; Alexander, K.; et al. HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America. J. Card. Fail. 2025, 31, 66–116.

  • 2.

    McDonagh, T.A.; Metra, M.; Adamo, M.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021, 42, 3599–3726.

  • 3.

    James, S.L.; Abate, D.; Abate, K.H.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858.

  • 4.

    Hu, H.; Li, J.; Wei, X.; et al. Elevated level of high-sensitivity cardiac troponin I as a predictor of adverse cardiovascular events in patients with heart failure with preserved ejection fraction. Chin. Med. J. 2023, 136, 2195–2202.

  • 5.

    Everett, R.J.; Treibel, T.A.; Fukui, M.; et al. Extracellular Myocardial Volume in Patients with Aortic Stenosis. J. Am. Coll. Cardiol. 2020, 75, 304–316.

  • 6.

    Xu, L.Y.; Xie, L.; Wang, J.; et al. Correlation between serum laminin levels and prognosis of acute myocardial infarction. Front. Cardiovasc. Med. 2022, 9, 936983.

  • 7.

    Dong, Y.; Yang, D.; Han, Y.; et al. Age and Gender Impact the Measurement of Myocardial Interstitial Fibrosis in a Healthy Adult Chinese Population: A Cardiac Magnetic Resonance Study. Front. Physiol. 2018, 9, 140.

  • 8.

    González, A.; Schelbert, E.B.; Díez, J.; et al. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. J. Am. Coll. Cardiol. 2018, 71, 1696–1706.

  • 9.

    Xu, Z.; Lu, D.; Yuan, J.; et al. Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R-Ankrd1-P53 Signaling Pathway. Int. J. Mol. Sci. 2022, 23, 13161.

  • 10.

    Chen, X.; Chen, X.; Shi, X.; et al. Curcumin attenuates endothelial cell fibrosis through inhibiting endothelial-interstitial transformation. Clin. Exp. Pharmacol. Physiol. 2020, 47, 1182–1192.

  • 11.

    Zhang, X.; Yang, S.; Hao, S.; et al. Myocardial fibrosis and prognosis in heart failure with preserved ejection fraction: A pooled analysis of 12 cohort studies. Eur. Radiol. 2024, 34, 1854–1862.

  • 12.

    Mewton, N.; Liu, C.Y.; Croisille, P.; et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2011, 57, 891–903.

  • 13.

    Seno, A.; Antiochos, P.; Lichtenfeld, H.; et al. Prognostic Value of T1 Mapping and Feature Tracking by Cardiac Magnetic Resonance in Patients with Signs and Symptoms Suspecting Heart Failure and No Clinical Evidence of Coronary Artery Disease. J. Am. Heart Assoc. 2022, 11, e020981.

  • 14.

    Ho, J.E.; Liu, C.; Lyass, A.; et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012, 60, 1249–1256.

  • 15.

    Asleh, R.; Enriquez-Sarano, M.; Jaffe, A.S.; et al. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. J. Am. Coll. Cardiol. 2019, 73, 2286–2295.

  • 16.

    Aurora, L.; Peterson, E.; Gui, H.; et al. Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction. Clin. Chim. Acta 2020, 510, 767–771.

  • 17.

    Lin, K.; Shi, D.; Wang, A.; et al. Noninvasive Monitoring of Early Cardiac Fibrosis in Diabetic Mice by [(68)Ga]Ga-DOTA-FAPI-04 PET/CT Imaging. ACS Omega 2024, 9, 17195–17203.

  • 18.

    Zhu, W.; Guo, F.; Wang, Y.; et al. 68Ga-FAPI-04 Accumulation in Myocardial Infarction in a Patient with Neuroendocrine Carcinoma. Clin. Nucl. Med. 2020, 45, 1020–1022.

  • 19.

    Sun, Y.; Sun, Y.; Li, Z.; et al. (18)F-FAPI PET/CT performs better in evaluating mediastinal and hilar lymph nodes in patients with lung cancer: Comparison with (18)F-FDG PET/CT. Eur. J. Med. Res. 2024, 29, 9.

  • 20.

    Koerber, S.A.; Röhrich, M.; Walkenbach, L.; et al. Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J. Nucl. Med. 2023, 64, 1712–1720.

  • 21.

    Verena, A.; Kuo, H.T.; Merkens, H.; et al. Novel (68)Ga-Labeled Pyridine-Based Fibroblast Activation Protein-Targeted Tracers with High Tumor-to-Background Contrast. Pharmaceuticals 2023, 16, 449.

  • 22.

    Huang, J.; Fu, L.; Hu, K.; et al. Automatic Production and Preliminary PET Imaging of a New Imaging Agent [(18)F]AlF-FAPT. Front. Oncol. 2021, 11, 802676.

  • 23.

    Altmann, A.; Haberkorn, U.; Siveke, J. The Latest Developments in Imaging of Fibroblast Activation Protein. J. Nucl. Med. 2021, 62, 160–167.

  • 24.

    Lindner, T.; Loktev, A.; Altmann, A.; et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J. Nucl. Med. 2018, 59, 1415–1422.

  • 25.

    Kang, J.Y.; Mun, D.; Park, M.; et al. Injured Cardiac Tissue-Targeted Delivery of TGFβ1 siRNA by FAP Aptamer-Functionalized Extracellular Vesicles Promotes Cardiac Repair. Int. J. Nanomed. 2025, 20, 2575–2592.

  • 26.

    Song, W.; Zhang, X.; He, S.; et al. (68)Ga-FAPI PET visualize heart failure: From mechanism to clinic. Eur. J. Nucl. Med. Mol. Imaging 2023, 50, 475–485.

  • 27.

    Paulus, W.J.; Zile, M.R. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure with Preserved Ejection Fraction Paradigm Revisited. Circ. Res. 2021, 128, 1451–1467.

  • 28.

    Yamada, Y.; Sadahiro, T.; Nakano, K.; et al. Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction. Circulation 2025, 151, 379–395.

  • 29.

    Anderson, K.R.; Sutton, M.G.; Lie, J.T. Histopathological types of cardiac fibrosis in myocardial disease. J. Pathol. 1979, 128, 79–85.

  • 30.

    Mori, D.; Miyagawa, S.; Kido, T.; et al. Adipose-derived mesenchymal stem cells preserve cardiac function via ANT-1 in dilated cardiomyopathy hamster model. Regen. Ther. 2021, 18, 182–190.

  • 31.

    Litviňuková, M.; Talavera-López, C.; Maatz, H.; et al. Cells of the adult human heart. Nature 2020, 588, 466–472.

  • 32.

    Feng, P.; Che, Y.; Gao, C.; et al. Profibrotic role of transcription factor SP1 in cross-talk between fibroblasts and M2 macrophages. iScience 2023, 26, 108484.

  • 33.

    Huang, X.; Hu, L.; Li, J.; et al. The relationship between inflammatory factors and heart failure: Evidence based on bidirectional Mendelian randomization analysis. Front. Cardiovasc. Med. 2024, 11, 1378327.

  • 34.

    Sun, F.; Wang, C.; Feng, H.; et al. Visualization of Activated Fibroblasts in Heart Failure with Preserved Ejection Fraction with [(18)F]AlF-NOTA-FAPI-04 PET/CT Imaging. Mol. Pharm. 2023, 20, 2634–2641.

  • 35.

    Varasteh, Z.; Mohanta, S.; Robu, S.; et al. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a (68)Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04. J. Nucl. Med. 2019, 60, 1743–1749.

  • 36.

    Zhang, X.; Song, W.; Qin, C.; et al. Non-malignant findings of focal (68)Ga-FAPI-04 uptake in pancreas. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2635–2641.

  • 37.

    Qin, C.; Shao, F.; Gai, Y.; et al. (68)Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with (18)F-FDG PET/CT. J. Nucl. Med. 2022, 63, 81–88.

  • 38.

    Pang, Y.; Zhao, L.; Fang, J.; et al. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy. J. Nucl. Med. 2023, 64, 1449–1455.

  • 39.

    Wang, J.; Yu, N.; Wang, G.; et al. 68Ga-FAPI-04 PET/CT in Assessment of Fibroblast Activation in Keloids: A Prospective Pilot Study. Clin. Nucl. Med. 2024, 49, 16–22.

  • 40.

    Watabe, T.; Liu, Y.; Kaneda-Nakashima, K.; et al. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: (64)Cu- and (225)Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. J. Nucl. Med. 2020, 61, 563–569.

  • 41.

    Makarov, I.; Voronkina, D.; Gurshchenkov, A.; et al. Are Endomyocardial Ventricular Biopsies Useful for Assessing Myocardial Fibrosis? J. Clin. Med. 2024, 13, 3275.

  • 42.

    Zhu, H.; Xie, K.; Qian, Y.; et al. Recent Progresses in the Multimodality Imaging Assessment of Myocardial Fibrosis. Rev. Cardiovasc. Med. 2024, 25, 5.

  • 43.

    Oda, S.; Funama, Y.; Kojima, S.; et al. Basic verification of myocardial extracellular volume quantification by prototype photon-counting detector computed tomography: A phantom study. J. Clin. Imaging Sci. 2025, 15, 8.

  • 44.

    van Oorschot, J.W.; Gho, J.M.; van Hout, G.P.; et al. Endogenous contrast MRI of cardiac fibrosis: Beyond late gadolinium enhancement. J. Magn. Reson. Imaging 2015, 41, 1181–1189.

  • 45.

    Jiang, Y.; Chen, Z.; He, Y. Comparison of 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT in Evaluating Lesion Stages in Constrictive Pericarditis. Clin. Nucl. Med. 2025, 50, e631–e632.

  • 46.

    Giesel, F.L.; Kratochwil, C.; Schlittenhardt, J.; et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4377–4385.

  • 47.

    Alonso Martinez, L.M.; Naim, N.; Saiz, A.H.; et al. A Reliable Production System of Large Quantities of [(13)N]Ammonia for Multiple Human Injections. Molecules 2023, 28, 4517.

  • 48.

    Kuhle, W.G.; Porenta, G.; Huang, S.C.; et al. Quantification of regional myocardial blood flow using 13N-ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 1992, 86, 1004–1017.

  • 49.

    Zhang, X.; Song, W.; Qin, C.; et al. Different displays of (13)N-NH(3) myocardial perfusion and cardiac (68)Ga-FAPI PET in immune checkpoint inhibitor-associated myocarditis-induced heart failure. Eur. J. Nucl. Med. Mol. Imaging 2023, 50, 964–965.

  • 50.

    Siebermair, J.; Köhler, M.I.; Kupusovic, J.; et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J. Nucl. Cardiol. 2021, 28, 812–821.

  • 51.

    Chandekar, K.R.; Prashanth, A.; Vinjamuri, S.; et al. FAPI PET/CT Imaging-An Updated Review. Diagnostics 2023, 13, 2018.

  • 52.

    Loganath, K.; Craig, N.; Barton, A.; et al. Cardiovascular positron emission tomography imaging of fibroblast activation: A review of the current literature. J. Nucl. Cardiol. 2025, 47, 102106.

  • 53.

    Mori, Y.; Dendl, K.; Cardinale, J.; et al. FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. Radiology 2023, 306, e220749.

  • 54.

    Mpanya, D.; Sathekge, M.; Klug, E.; et al. Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease. Front. Nucl. Med. 2023, 3, 1224905.

  • 55.

    Kiani, M.; Jokar, S.; Hassanzadeh, L.; et al. Recent Clinical Implications of FAPI: Imaging and Therapy. Clin. Nucl. Med. 2024, 49, e538–e556.

  • 56.

    Li, H.; Wei, Y.; Qin, Z.; et al. (18)F-FAPI-74 Positron Emission Tomography/Computed Tomography Noninvasively Monitoring the Fibrosis of Cardiac Allograft Vasculopathy. J. Am. Heart Assoc. 2025, 14, e041169.

  • 57.

    Liang, S.; Hou, P.; Wang, X.; et al. Comparison of (18)F-FAPI-42 PET for Detecting Cardiac Fibroblast Activation in Dilated Cardiomyopathy with Histopathology and CMR. JACC Cardiovasc. Imaging 2025, 18, 997–1009.

  • 58.

    Zeng, X.; Zhao, R.; Wu, Z.; et al. [(18)F]-FAPI-42 PET/CT assessment of Progressive right ventricle fibrosis under pressure overload. Respir. Res. 2023, 24, 270.

  • 59.

    Hosseini, A.; Haj-Yehia, E.; Korste, S.; et al. How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice. J. Nucl. Med. 2025, 66, 1757–1763.

  • 60.

    Wang, G.; Yang, Q.; Wu, S.; et al. Molecular imaging of fibroblast activity in pressure overload heart failure using [(68)Ga]Ga-FAPI-04 PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2023, 50, 465–474.

  • 61.

    Diekmann, J.; Koenig, T.; Zwadlo, C.; et al. Molecular Imaging Identifies Fibroblast Activation Beyond the Infarct Region After Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2021, 77, 1835–1837.

  • 62.

    Jiang, M.; Zhang, G.; Li, L.; et al. Case Report: A case report of myocardial fibrosis activation assessment after unstable angina using (68)Ga-FAPI-04 PET/CT. Front. Cardiovasc. Med. 2024, 11, 1332307.

  • 63.

    Zhou, W.; Sun, J.; Wang, F.; et al. Displays of 18F-FAPI PET/CT in Myocarditis with Variable Symptom Durations. Clin. Nucl. Med. 2023, 48, 799–801.

  • 64.

    Gu, Y.; Han, K.; Zhang, Z.; et al. (68)Ga-FAPI PET/CT for molecular assessment of fibroblast activation in right heart in pulmonary arterial hypertension: A single-center, pilot study. J. Nucl. Cardiol. 2023, 30, 495–503.

  • 65.

    Ruiz-Hueso, R.; Salamanca-Bautista, P.; Quesada-Simón, M.A.; et al. Estimating the Prevalence of Cardiac Amyloidosis in Old Patients with Heart Failure-Barriers and Opportunities for Improvement: The PREVAMIC Study. J. Clin. Med. 2023, 12, 2273.

  • 66.

    Wang, X.; Guo, Y.; Gao, Y.; et al. Feasibility of (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. JACC Cardiovasc. Imaging 2022, 15, 1960–1970.

  • 67.

    Luo, R.; Zhao, Z.; Zhang, C.; et al. Evaluation of myocardial fibrosis and wall motion abnormality with (68)Ga-FAPI PET/MR in coronary heart disease. EJNMMI Res. 2025, 15, 89.

  • 68.

    Yang, Q.; Xue, S.; Ren, C.; et al. Fibroblast activation protein-targeted PET/CT in multiple non-ischemic cardiomyopathies. Eur. J. Nucl. Med. Mol. Imaging 2025, 52, 5044–5049.

  • 69.

    Wang, L.; Zhang, Z.; Zhao, Z.; et al. (68)Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension. J. Nucl. Cardiol. 2022, 29, 1475–1477.

  • 70.

    Barton, A.K.; Craig, N.J.; Loganath, K.; et al. Myocardial Fibroblast Activation After Acute Myocardial Infarction: A Positron Emission Tomography and Magnetic Resonance Study. J. Am. Coll. Cardiol. 2025, 85, 578–591.

  • 71.

    Zhang, M.; Quan, W.; Zhu, T.; et al. [(68)Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: Potential role of predicting left ventricular remodeling. Eur. J. Nucl. Med. Mol. Imaging 2023, 50, 839–848.

  • 72.

    Diekmann, J.; Koenig, T.; Thackeray, J.T.; et al. Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome. J. Nucl. Med. 2022, 63, 1415–1423.

  • 73.

    Aghajanian, H.; Kimura, T.; Rurik, J.G.; et al. Targeting cardiac fibrosis with engineered T cells. Nature 2019, 573, 430–433.

  • 74.

    Wang, L.; Wang, Y.; Wang, J.; et al. Myocardial Activity at (18)F-FAPI PET/CT and Risk for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Radiology 2023, 306, e221052.

  • 75.

    Wang, X.; Shen, K.; Zhang, Y.; et al. Molecular Stratification of Light-Chain Cardiac Amyloidosis with (18)F-Florbetapir and (68)Ga-FAPI-04 for Enhanced Prognostic Precision. JACC Cardiovasc. Imaging 2025, 18, 323–336.

  • 76.

    Zhao, Y.; Su, X.; Xiang, B.; et al. Application of (68)Ga- and (177)Lu-Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis After Myocardial Infarction. MedComm 2025, 6, e70198.

  • 77.

    Kessler, L.; Kupusovic, J.; Ferdinandus, J.; et al. Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PET. Clin. Nucl. Med. 2021, 46, 807–813.

  • 78.

    Chen, B.X.; Xing, H.Q.; Gong, J.N.; et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 1211–1222.

  • 79.

    Suh, M.; Gil, J.; Kang, Y.K.; et al. Aged-Related Fibroblast Activation Protein Expression in Skeletal Muscles Evaluated by PET Imaging. J. Cachexia Sarcopenia Muscle 2025, 16, e13730.

  • 80.

    Luo, Y.; Pan, Q.; Zhou, Z.; et al. (68)Ga-FAPI PET/CT for Rheumatoid Arthritis: A Prospective Study. Radiology 2023, 307, e222052.

  • 81.

    Kratochwil, C.; Flechsig, P.; Lindner, T.; et al. (68)Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J. Nucl. Med. 2019, 60, 801–805.

  • 82.

    Kessler, L.; Ferdinandus, J.; Hirmas, N.; et al. Pitfalls and Common Findings in (68)Ga-FAPI PET: A Pictorial Analysis. J. Nucl. Med. 2022, 63, 890–896.

  • 83.

    Notohamiprodjo, S.; Nekolla, S.G.; Robu, S.; et al. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using (68)Ga-FAPI-04. J. Nucl. Cardiol. 2022, 29, 2254–2261.

  • 84.

    Rep, S.; Tomse, P.; Jensterle, L.; et al. Image reconstruction using small-voxel size improves small lesion detection for positron emission tomography. Radiol. Oncol. 2022, 56, 142–149.

  • 85.

    Kolthammer, J.A.; Su, K.H.; Grover, A.; et al. Performance evaluation of the Ingenuity TF PET/CT scanner with a focus on high count-rate conditions. Phys. Med. Biol. 2014, 59, 3843–3859.

  • 86.

    Zhao, L.; Wen, X.; Xu, W.; et al. Clinical Evaluation of (68)Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin α(v)β(3) in Various Cancer Types. J. Nucl. Med. 2023, 64, 1210–1217.

  • 87.

    Ding, J.; Zhang, H.; Chen, X.; et al. Enhanced detection of damaged myocardium and risk stratification in hypertrophic cardiomyopathy using integrated [(68)Ga]Ga-FAPI-04 PET/CMR imaging. Eur. J. Nucl. Med. Mol. Imaging 2024, 52, 98–108.

  • 88.

    Zhang, N.; Ma, Q.; You, Y.; et al. CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction. Int. J. Biol. Sci. 2022, 18, 1271–1287.

  • 89.

    Werner, R.A.; Koenig, T.; Diekmann, J.; et al. CXCR4-Targeted Imaging of Post-Infarct Myocardial Tissue Inflammation: Prognostic Value After Reperfused Myocardial Infarction. JACC Cardiovasc. Imaging 2022, 15, 372–374.

  • 90.

    Gao, H.; Tang, H.; Zheng, Z.; et al. One-Stop 68Ga-FAPI/18F-FDG Total-Body PET/CT Scan: More Theranostics Information Available. Clin. Nucl. Med. 2025, 50, e253–e261.

Share this article:
Download PDF
DOI
10.53941/icirculation.2026.100003
Issue
Volume 1, Issue 1
How to Cite
Guo, H.; Li, J. The Latest Progress of Targeting Fibroblast Activating Protein PET/CT Molecular Imaging in Heart Failure. iCirculation 2026, 1 (1), 3. https://doi.org/10.53941/icirculation.2026.100003.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.